Laying The Groundwork To Measure The Impact Of DCTs

By: Cindy Henderson, Chief Commercial Officer

Back in November, Veristat sent its Chief Commercial Officer Cindy Henderson to participate in the Tufts CSDD Roundtable. She was joined by Ken Getz, the Tufts CSDD team, in addition to several other pharmaceutical and CRO colleagues.

“It is part of our company’s DNA to stay ahead of the driving forces in the industry so that we can best serve as a knowledgeable partner for our clients, most of whom are small to mid-size organizations involved in rare diseases and novel therapies,” wrote Henderson.

During the discussion, roundtable participants aimed to:

• Come to a consensus on the meaning of DCT;
• Identify the challenges to DCT adoption;
• Begin to understand how best to evaluate;
• Understand the value proposition for DCT deployments; and
• Identify the metrics and KPIs to measure their ROI.

In sharing her key takeaways from the invite-only program, gain insight into quantifying the value proposition of decentralized clinical trial deployments.